APLS

Apellis Pharmaceuticals, Inc. develops and commercializes therapeutic compounds for serious complement-mediated diseases. Headquartered in Waltham, Massachusetts, the biopharmaceutical company focuses on inhibiting the complement system, a part of the immune system that, when overactive, contributes to various autoimmune and inflammatory conditions. Apellis markets SYFOVRE (pegcetacoplan injection), the first and only FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration, which launched in 2023. The company also commercializes EMPAVELI (pegcetacoplan), approved for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Apellis operates with a targeted complement inhibition platform centered on pegcetacoplan, a synthetic cyclic peptide that binds to complement protein C3 and its activation fragment C3b. The company maintains research and development facilities in Massachusetts and employs approximately 800 people. In 2024, Apellis received additional FDA approvals expanding SYFOVRE's commercial potential and continues advancing its pipeline of complement-targeted therapies for conditions including immune complex membranoproliferative glomerulonephritis and amyotrophic lateral sclerosis. The company collaborates with Swedish Orphan Biovitrum AB on international commercialization of EMPAVELI and ASPAVELI in certain markets outside the United States. Apellis competes in the specialty pharmaceutical sector focused on rare diseases and retinal conditions.